scholarly journals Clinical genetic features and related survival implications in patients with surgically resected large-cell lung cancer

2019 ◽  
Vol Volume 11 ◽  
pp. 5489-5499 ◽  
Author(s):  
Fang Wang ◽  
Jia-Bin Lu ◽  
Xiao-Yan Wu ◽  
Yan-Fen Feng ◽  
Qiong Shao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Clinical Genetic ◽  
Genetic Features ◽  
Large Cell Lung Cancer ◽  
Related Survival

scholarly journals A CASE OF RECURRENT LARGE CELL LUNG CANCER PRESENTING WITH ILEUS

2008 ◽  
Vol 69 (6) ◽  
pp. 1341-1344 ◽  
Author(s):  
Motohiro NISHIMURA ◽  
Masao KOBAYASHI ◽  
Kanji KAWAI ◽  
Yasuhiko TANIOKA ◽  
Kenichiro HAMAGASHIRA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Large Cell Lung Cancer

scholarly journals Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis

2021 ◽  
Vol 11 ◽  
Author(s):  
Tianwei Xu ◽  
Chenchen Wei ◽  
Xiaoteng Zou ◽  
Binbin Lu ◽  
Zhaoxia Wang
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Case Reports ◽  
Antiangiogenic Therapy ◽  
Local Treatment ◽  
Chemotherapy Resistance ◽  
Large Cell ◽  
Term Survival ◽  
Good Efficacy ◽  
Large Cell Lung Cancer

Undifferentiated large-cell lung cancer is a rare type of non-small cell lung cancer (NSCLC) with a poor prognosis. It is insensitive to chemotherapy and easily develops drug resistance. Analysis of the Surveillance, Epidemiology, and End Results (SEER) database showed that patients with stage IV undifferentiated large-cell lung cancer had a median overall survival (OS) of only 4 months and that those who received chemotherapy had a median OS of only 5 months longer than those who did not. For the first time, we report a case of advanced large-cell undifferentiated lung cancer with rare tonsil metastasis. The patient developed resistance after 3 months of platinum-based systemic chemotherapy and local treatment. Antiangiogenic therapy has been continuously progressing and has shown certain efficacy in treating many malignant tumors, such as lung cancer. However, there are no relevant studies or case reports on antiangiogenic therapy in the treatment of undifferentiated large-cell lung cancer. Anlotinib, an orally delivered small-molecule antiangiogenic tyrosine kinase inhibitor (TKI), was administered to this patient after chemotherapy resistance occurred, and the outcome was assessed as continued stable disease (SD). As of the last follow-up evaluation, the progression-free survival (PFS) of the patient was 21.5 months, and the OS was 27.5 months. Retrospective immunohistochemical analysis showed that the patient was positive for one of the targets of anlotinib (PDGFR). In general, the findings in this case suggest that anlotinib may be an option with good efficacy for patients with large-cell undifferentiated lung cancer after chemotherapy resistance that may have good efficacy and also suggest that PDGFR may be the target underlying this effect.

scholarly journals P2.02-001 Advanced Large Cell Lung Cancer; Biological Behavior and Prognostic Factors

2017 ◽  
Vol 12 (1) ◽  
pp. S846
Author(s):  
Hala Aziz ◽  
M. Rahouma ◽  
Iman Loay ◽  
Galal Ghaly ◽  
Mohamed Kamel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Biological Behavior ◽  
Large Cell Lung Cancer

scholarly journals A CASE OF SMALL BOWEL METASTASIS OF LARGE CELL LUNG CANCER

1997 ◽  
Vol 58 (5) ◽  
pp. 1003-1007
Author(s):  
Nahoko IKEDA ◽  
Nobuyuki TOYAMA ◽  
Tasuku WAINAI ◽  
Takeshi YOSHIDA ◽  
Ritsu KOHIYAMA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Bowel ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Small Bowel Metastasis ◽  
Large Cell Lung Cancer

scholarly journals Large Cell Lung Cancer Complicated with Chronic Myelogenous Leukemia

Haigan ◽  
2009 ◽  
Vol 49 (6) ◽  
pp. 844-846
Author(s):  
Hidehito Matsuoka ◽  
Takeshi Hatta ◽  
Takeyuki Kushima
Keyword(s):  
Lung Cancer ◽  
Chronic Myelogenous Leukemia ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Myelogenous Leukemia ◽  
Large Cell Lung Cancer

Tricarbonylrhenium(i) complexes with 2-acetylpyridine-derived hydrazones are cytotoxic to NCI-H460 human large cell lung cancer

2016 ◽  
Vol 40 (9) ◽  
pp. 7379-7387 ◽  
Author(s):  
Camila Vargas Garcia ◽  
Gabrieli Lessa Parrilha ◽  
Bernardo Lages Rodrigues ◽  
Sarah Fernandes Teixeira ◽  
Ricardo Alexandre de Azevedo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Antiproliferative Activity ◽  
Mode Of Action ◽  
Large Cell ◽  
H460 Cells ◽  
Large Cell Lung Cancer ◽  
Hydrazone Complexes

Tricarbonylrhenium(i)-hydrazone complexes showed antiproliferative activity against NCI-H460 cells. The mode of action involves apoptosis and ROS scavenge.

scholarly journals MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer

2017 ◽  
Vol 21 (12) ◽  
pp. 3741-3751 ◽  
Author(s):  
Yanlei Li ◽  
Baocun Sun ◽  
Xiulan Zhao ◽  
Xudong Wang ◽  
Danfang Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Vasculogenic Mimicry ◽  
Large Cell ◽  
Large Cell Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document